X4P 001

Drug Profile

X4P 001

Alternative Names: AMD-070; AMD11070; X4P 001 RD; X4P-001-IO; X4P001

Latest Information Update: 02 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnorMED
  • Developer X4 Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Immunodeficiency disorders
  • Phase I/II Renal cell carcinoma
  • Phase I Malignant melanoma; Solid tumours
  • Discontinued HIV-1 infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Phase-II/III clinical trials in Immunodeficiency disorders (WHIM Syndrome; In adolescents, In adults) in USA (PO) (NCT03005327)
  • 30 Nov 2016 Pharmacodynamics data from a preclinical study in Renal cell carcinoma presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (EORTC-NCI-AACR 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top